November 19, 2026 |
1 min read |
In this episode of Denatured, you’ll hear from Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Watch on YouTube
In this episode of Denatured, you’ll listen to Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We examine why the FDA is placing renewed emphasis on drug repurposing and what it will take to transform existing molecules into effective new therapies.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Daniel Tillett, CEO, Racura Oncology
Sten Sörensen, CEO, Cereno Scientific
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.